Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.78 |
| ▸ | NPC1 | O15118 | 3/20 | 0.74 |
| ▸ | RAB9A | P51151 | 3/20 | 0.74 |
| ▸ | KCNK3 | O14649 | 6/20 | 0.71 |
| ▸ | KCNK9 | Q9NPC2 | 5/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | NT5E | P21589 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.66 |
| ▸ | MEN1 | O00255 | 6/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4257440 | 0.88 | NPC1 (0.81) | TP53NPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL30048093 | 0.88 | NPC1 (0.81) | TP53NPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL27180026 | 0.88 | TP53 (1.00) | TP53NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL19156946 | 0.86 | KCNK3 (0.79) | TP53NPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL5389532 | 0.86 | HDAC8 (0.75) | TP53NPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL5380687 | 0.85 | TP53 (1.00) | TP53NPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL30555199 | 0.85 | TP53 (1.00) | TP53NPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL12310445 | 0.85 | TP53 (0.69) | TP53NPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL3675929 | 0.85 | TP53 (0.86) | TP53NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL259666 | 0.85 | KCNK3 (0.87) | TP53NPC1RAB9AKCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20160171150-A1 | Chemical Modulators of Pro-Apoptotic BAX and BCL-2 Polypeptides | DANA-FARBER CANCER INSTITUTE, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20160171150-A1 | Chemical Modulators of Pro-Apoptotic BAX and BCL-2 Polypeptides | DANA-FARBER CANCER INSTITUTE, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20110218155-A1 | CHEMICAL MODULATORS OF PRO-APOPTOTIC BAX AND BCL-2 POLYPEPTIDES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110218155-A1 | CHEMICAL MODULATORS OF PRO-APOPTOTIC BAX AND BCL-2 POLYPEPTIDES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | TP53 1/4885NPC1 715/4885RAB9A 1412/4885 |
| US-20110218155-A1 | CHEMICAL MODULATORS OF PRO-APOPTOTIC BAX AND BCL-2 POLYPEPTIDES | BAX, BCL2, BCL2L1 | TP53 61/4885NPC1 4437/4885RAB9A 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.